Keramatian K, Chakrabarty T, Saraf G, et al. - This systematic review summarizes recently published randomized controlled trials (RCTs) on the safety and effectiveness of atypical antipsychotics in bipolar disorder (BD). Several studies have found quetiapine monotherapy to be effective in acute bipolar I (BDI) and bipolar II (BDII) depression. Furthermore, in treatment-resistant bipolar depression, quetiapine adjunctive therapy outperformed placebo. Recently published RCTs generally support the effectiveness of atypical antipsychotics in various stages of BD. Future research should concentrate on understudied populations such as pediatric BD, geriatric BD, and BDII, as well as cognitive functioning and quality of life measures.